Selank Peptide vs Semax: What Does the Research Say?

What Is Selank?

Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. The compound carries the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and has been studied primarily for anxiolytic and nootropic properties. Research has examined its effects on enkephalin metabolism, cytokine modulation, hippocampal synaptic activity, and functional brain connectivity. Semax — a separate compound and an analog of the ACTH 4–10 fragment — is its most frequent comparator in the literature, and the two are sometimes tested in tandem.

---

What Is Selank Studied For?

Research on Selank goes back to 2002 — nearly 20 years — with studies continuing through 2023.

1. Anxiety Modulation — A 2002 observational examination of patients with anxiety and phobic disorders (classified by DSM-4 criteria) found that Selank inhibited enkephalin-degrading enzymes in blood, offering a plausible biochemical account for its anxiolytic profile.

2. Adjunct to Pharmacotherapy in Anxiety Disorders — A randomized controlled trial enrolling 70 patients (30 monotherapy, 40 combination-arm) compared phenazepam alone against phenazepam combined with Selank in anxiety-phobic, hypochondriacal, and related presentations, with the combination arm reported to show improved tolerability outcomes.

3. Stress-Related Cytokine Modulation — A 2022 preclinical study in rodents under a "social stress" paradigm reported that Selank attenuated stress-induced elevations of IL-1β, IL-6, and related cytokines, suggesting an immunomodulatory dimension to its activity.

4. Opioid Withdrawal Attenuation — A 2022 preclinical study in outbred rats using a naloxone-precipitated morphine withdrawal model found that a single intraperitoneal administration of Selank reduced the composite withdrawal index by 39.6% and decreased convulsive reactions by roughly ninefold compared to controls.

5. Resting-State Brain Connectivity — A human observational study in 52 healthy participants assessed whole-brain functional connectivity changes following Selank and Semax administration, identifying distinct connectivity shifts in amygdala and dorsolateral prefrontal cortex networks. Note that the human data on brain connectivity (as noted in the source concentration section below) clusters around a small number of research groups.

---

How Do Selank and Semax Differ Mechanistically?

Selank and Semax share a common origin in Russian neuropeptide research but act through distinct primary mechanisms. Selank's mechanism centers on enkephalin metabolism: a 2002 human observational study found that it inhibits enkephalin-degrading enzymes — specifically enkephalinase — in blood samples from patients with anxiety disorders, effectively prolonging the half-life of endogenous opioid peptides. That enzymatic inhibition is the most granular mechanistic account in the indexed literature.

Semax, by contrast, derives from a fragment of adrenocorticotropic hormone and is understood to engage ACTH-related receptor pathways rather than opioid-adjacent ones. The two compounds arrive at overlapping behavioral outputs — reduced anxiety, altered stress responses — through non-identical upstream biology.

A 2017 preclinical study applying Selank directly to rat hippocampal slices added a synaptic dimension: the compound increased both the amplitude and discharge rate of spontaneous inhibitory postsynaptic currents (IPSCs) in pyramidal CA1 neurons, with the enhancement scaling across the tested concentration range of 1–8 μM. This GABAergic-adjacent inhibitory potentiation is not a reported feature of Semax, which points toward neurotrophic and cognitive-enhancement pathways instead.

---

What Does Animal Research Show for Each Compound?

Most of the comparative rodent work comes from a 2018 preclinical study that tested both peptides in rats with 6-hydroxydopamine (6-OHDA) induced parkinsonism — a standard model for dopaminergic neuron loss approximating Parkinson's disease pathology. That study reported behavioral effects for both Selank and Semax in the lesioned animals, though the authors were examining locomotor and behavioral endpoints rather than mechanistic separation of the two compounds. The findings are preliminary and limited to this single rodent model; no replication study appears in the indexed pool.

The 2022 rodent withdrawal study provides Selank-specific data with no Semax comparator: in outbred rats, a single dose of Selank reduced the total morphine withdrawal index by 39.6%, attenuated convulsive reactions, ptosis, and posture disorders, and increased exploratory behavior — measured as time spent in the open arms of an elevated plus maze — by ninefold. Semax was not tested in that paradigm.

The 2022 cytokine study similarly examined Selank alone, not in comparison with Semax. Rodents under social stress showed elevated IL-1β and IL-6; Selank administration attenuated those elevations. No equivalent Semax cytokine study appears in the indexed literature pool.

Feature	Selank (animal data)	Semax (animal data)
Parkinsonism model (6-OHDA rats)	Behavioral effects reported	Behavioral effects reported
Opioid withdrawal model	Reduced withdrawal index 39.6%	Not tested in this pool
Social stress cytokines	IL-1β, IL-6 attenuation	Not tested in this pool
Hippocampal IPSCs	Amplitude/frequency increase	Not tested in this pool

---

What Does Human Research Show for Each Compound?

Three of the eight indexed studies include human participants, and the research concentration here matters: two of the three human studies appear in the same journal (Bulletin of Experimental Biology and Medicine or the Doklady Biological Sciences series), and author Myasoedov N F appears across multiple primary studies. This clustering reflects the broader reality that Selank's human research base is largely concentrated within a small number of Russian-affiliated research groups, and independent replication in Western trial registries is sparse.

The most clinically structured human study is a 2015 RCT enrolling 70 patients with anxiety-phobic, hypochondriacal, and related disorders. It compared phenazepam monotherapy (n = 30) against combination treatment with Selank plus phenazepam (n = 40). The combination arm was associated with improved tolerability relative to phenazepam alone. This is a relatively small trial, and the design does not include a Selank-only arm, so the study cannot isolate Selank's independent contribution.

The 2021 human observational study in 52 healthy participants measured resting-state functional connectivity using predefined regions of interest — the amygdala and dorsolateral prefrontal cortex — following administration of both Selank and Semax. The study reported distinct connectivity changes for each compound, suggesting that despite behavioral overlap the two peptides engage different network-level patterns. Sample size, blinding status, and study design details are not fully specified in the indexed abstract, which limits interpretive confidence.

The 2002 human observational study examined enkephalinase activity in blood from patients with anxiety and phobic disorders. It found reduced enkephalin half-life and lower total enkephalinase activity in patients with generalized anxiety — but not in those with panic disorder or agoraphobia — and reported that Selank inhibited these degrading enzymes. This study did not include a Semax comparator.

Semax has no standalone human trial in the provided study pool. All head-to-head human data for the two compounds comes from the single 2021 functional connectivity study, which observed both in the same 52-participant sample.

---

What Is Still Unknown?

Several gaps define the limits of available evidence. No head-to-head RCT comparing Selank directly against Semax exists in the indexed literature. The parkinsonism model study tested both compounds in rats but was not powered or designed to draw mechanistic comparisons between them. The functional connectivity study in humans was observational with an unclear blinding and control structure.

The cytokine findings and opioid withdrawal data for Selank are each supported by single preclinical studies with no independent replication. The RCT evidence comes from one small trial with a combination design that prevents attributing outcomes to Selank alone. Oral bioavailability, blood-brain barrier penetration in humans, and long-term safety have not been addressed in this study pool.

Research to date is concentrated in Russian-affiliated laboratories, with minimal indexed replication from independent international groups. Whether the functional connectivity or anxiolytic findings translate across populations, doses, and clinical contexts remains an open empirical question. The compound classified as PMID 37677054 in the study pool — a 2023 cardiovascular research paper on atrial fibrillation modelling using human-induced pluripotent stem cells — does not contain findings attributable to Selank and is excluded from this analysis accordingly.

---

Where Can I Buy Selank?

Selank is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---